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Combined treatment with anti-CD20 (rituximab) and
CHOP in relapsed advanced-stage follicular lymphomas
We studied the safety and efficacy of combined treatment
with rituximab plus CHOP in 16 patients with relapsed
advanced-stage follicular lymphomas. The intent-to-treat
overall response rate (ORR) was 88%, 75% complete remis-
sions (CR) and 13% partial remissions (PR). At a median fol-
low-up of 18 months, 63% of the patients are alive (50% CR).
The combination of rituximab and CHOP in relapsed advanced-
stage follicular lymphomas achieves high ORRs and CRs, with
low toxicity except for in previously autografted patients. 
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Non-Hodgkin’s lymphomas (NHLs) are a diverse group of lym-
phoid neoplasms that range from indolent malignancies to rapid-
ly growing and highly aggressive tumors. Follicular lymphomas
(FL) represent the second most frequent type of B-cell NHLs,
which usually present as a disseminated disease with an indolent
course. Although a high initial response rate is achieved, repeat-
ed relapses occur with progressively lower response rates and
shorter durations. The efficacy and safety of rituximab as single-
agent therapy1-4 or in combination with interferon-α 25 has been
demonstrated in patients with either relapsed or refractory low
grade lymphomas, as well as first-line therapy in this type of
lymphomas.6,7 Only one study has been reported8 of combined
treatment with rituximab and CHOP in low grade lymphomas,
achieving higher response rates than rituximab as single agent
therapy.
The current study is an open-label non-randomized multicen-
ter phase II study designed to investigate the toxicity and effi-
cacy of rituximab plus CHOP in the treatment of patients with
relapsed advanced follicular lymphoma. We included patients
with CD20 positive relapsed follicular lymphoma according to
the REAL classification, whatever the cell type, between 18 and
70 years of age. They had disease stage III or IV according to the
Ann-Arbor classification, ECOG <2 and adequate renal and
hepatic functions.
The treatment schedule consisted of six intravenous infusions
of rituximab (375 mg/m2) on days 1, 8, 78, 85, 155, 162 (2 ini-
tial infusions to reduce tumor mass and 2 final infusions to end
up with minimal residual disease), and six standard cycles of
CHOP on days 15, 36, 57, 92, 113, 134. Treatment was discon-
tinued if disease progression was observed or if a severe adverse
therapy-related event appeared. Patients were evaluated for dis-
ease status at base line, after the third cycle of CHOP, at the end
of treatment and every three months thereafter. Response was
evaluated following the criteria of Cheson et al.9 Response cat-
egories consisted of complete response (CR), partial response (PR)
and no response (NR) or progressive disease (PD). Toxicity was
evaluated according to the WHO criteria.
Results of the descriptive analysis are expressed as median
and range for continuous data and number of cases with their
proportion for qualitative data. Survival analysis was performed
at the univariate level by means of Kaplan-Meier techniques.
Sixteen patients were enrolled in this study in 4 centers from July
1998 to August 2000. The median age was 61 years (range: 40-
70 years) and 12 (75%) were males. All of them had received at
least one prior therapy (median 2; range 1-6) and three cases
(19%) had been previously submitted to an autologous bone
marrow transplant. The median time between diagnosis and
inclusion in the study was 35 months (range: 8-143 months)
(Table 1).
Infusional toxicity of rituximab appeared in 50% of the
patients, usually mild and in all cases this only occurred with the
first infusion. It was managed by adjustments of the infusion
rate and was not a cause of treatment withdrawal. CHOP toxic-
ity was observed in 8 patients (50%), mainly hematologic, with
grade IV neutropenia in 5 patients. All three patients who had
previously undergone a peripheral stem cell transplant did not
complete treatment, two due to hematologic toxicity and one due
to viral hepatitis B reactivation.
The intent-to-treat analysis showed 12 (75%) CR and 2 (13%)
PR with an 88% ORR (Table 1). Of the 12 patients in CR, 4 (33%)
patients relapsed (mean duration of CR of 14 months) (Figure 1).
With a median follow-up of 18 months, 10 patients (63%) are
alive, 8 (50%) in CR and 2 (13%) in PR.
We report a trial evaluating the clinical efficacy and safety of
combined treatment with rituximab and CHOP in relapsed
advanced-stage follicular lymphomas. 
Rituximab has been used as single-agent therapy1-4 or in com-
bination with interferon-α 2a5 in relapsed or refractory follicu-
lar lymphomas achieving ORRs of approximately 50% (15% CR),
as well as a single agent in first line low grade lymphomas6,7 with
70% ORRs (20% CR).
Table 1. Patient’s characteristics at the time of inclusion in
the  trial, treatment response and status.
Pat. Sex Age Num Time Response Status
1 M 46 2 (ASCT) 11m Withdrawn toxicity PR Died progression +16m
2 F 66 6 38m PR Died progression +10m
3 M 64 2 85m CR CR +11m
4 M 69 3 65m CR Relapse +3m
Died progression +12m
5 M 63 1 27m Progression Died progression +10m
6 M 59 3 64m CR CR +2m
7 M 66 2 143m CR CR +13m
8 M 43 2 (ASCT) 60m Withdrawn toxicity Died progression +14m
Progression
9 M 62 2 31m CR CR +10m
10 M 63 1 13m CR CR +6m
11 M 49 1 15m CR CR +18m
12 F 48 2 92m CR CR +18m
13 M 39 1 5m CR Relapse +3m. PR +5m
14 F 39 2 (ASCT) 41m Withdrawn VHB Relapse +16m. PR +4m
reactivation. CR
15 M 66 2 8m CR Relapse +7m
Died progression +9m
16 F 45 1 11m CR CR +17m
F= female; M= male; ASCT= autologous stem cell transplant.
CR: complete remission; PR: partial remission.
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These response rates, together with the fact that rituximab
enhances the in vitro efficacy of conventionally used cytotoxic
drugs,10 led to the use of combined treatment using anti-CD20
with conventional chemotherapy. Czuczman et al.8 included 40
patients with low grade or follicular lymphomas (31 untreated
and 9 previously treated lymphomas) with an intent-to-treat
ORR of 95% (55% CR) (89% ORR in the previously treated
patients (56% CR)).
In our group of previously treated follicular lymphomas the
intent-to-treat ORR was 88% (75% CR), similar to that obtained
by Czuczman et al.,8 which significantly improves the response
rates obtained with conventional chemotherapy.
Rituximab in combination with CHOP chemotherapy in
patients with relapsed advanced-stage follicular lymphomas is
associated with high ORRs and high CRs, together with low tox-
icity, except for in previously transplanted patients. These results
encourage the use of rituximab as first-line therapy in combina-
tion with other effective agents.
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Figure 1. Disease free survival curve of patients who achieved
a CR. The mean duration of CR is of 14 months.
